The global blood glucose monitoring market is estimated to be valued at USD 18.85 Bn in 2024 and is expected to exhibit a CAGR of 10.2% during the forecast period (2024-2031). Blood glucose monitoring is crucial for managing diabetes as it helps patients monitor their blood sugar levels and take corrective measures on a regular basis. Easy availability and affordability of self-monitoring devices along with growing awareness about diabetes care have been driving the greater adoption of blood glucose monitoring solutions globally. In addition, technological advancements leading to the development of innovative monitoring devices with enhanced features for accuracy, convenience, and connectivity are expected to further propel the market growth in the coming years.

Market Dynamics:

The global blood glucose monitoring market has been witnessing steady growth attributed to rising diabetic population worldwide coupled with growing focus on diabetes management. Various factors, such as increasing prevalence of obesity and sedentary lifestyles, are contributing to the diabetes burden globally, which, in turn, is driving the adoption of blood glucose monitoring devices. Additionally, the development of user-friendly and affordable monitoring solutions along with favorable reimbursement policies in developed regions are encouraging the greater uptake of self-monitoring devices. However, high costs associated with advanced blood glucose monitors remains a key challenge, especially in developing countries. Moreover, vulnerabilities to cyber threats and data breaches could hamper the transition towards connected monitoring devices. Nonetheless, ongoing technological upgrades including the development of minimally invasive continuous glucose monitoring systems presents bright prospects for market players.

Key Features of the Study:

• This report provides an in-depth analysis of the global blood glucose monitoring market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2024–2031), considering 2023 as the base year.
• It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global blood glucose monitoring market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study Medtronic, ACON Laboratories, Inc., Senseonics, Inc., Medisana AG, Bionime Corporation, AgaMatrix Inc., ARKRAY, Inc., Rossmax International Ltd., Dexcom, Inc., Nipro Group, B. Braun SE, Nova Biomedical, LifeScan IP Holdings, LLC, Ascensia Diabetes Care Holdings AG, Nemaura, Terumo Corporation, and Hoffmann-La Roche Ltd.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• The global blood glucose monitoring market caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global blood glucose monitoring market.

Detailed Segmentation-

• By Type:
  • Self-monitoring blood glucose devices
  • Continuous glucose monitoring devices
  • Flash glucose monitoring devices
• By Component:
  • Glucometer devices
  • Test strips
  • Lancets
  • Sensors
  • Others
• By End User:
  • Hospitals
  • Homecare Settings
  • Ambulatory Care Settings
  • Others
• By Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa

Company Profiles:

• Medtronic
• ACON Laboratories, Inc.
• Senseonics, Inc.
• Medisana AG
• Bionime Corporation
• AgaMatrix Inc.
• ARKRAY, Inc.
• Rossmax International Ltd.
• Dexcom, Inc.
• Nipro Group
• Braun SE
• Nova Biomedical 
• LifeScan IP Holdings, LLC
• Ascensia Diabetes Care Holdings AG
• Nemaura
• Terumo Corporation
• Hoffmann-La Roche Ltd.